In spite of enormous scientific breakthrougs in terms of determining cardiovascular risk, the challenge remains on how to fully determine cardiovascular risk for the specific patient. With an aging population and newer, better but also more expensive treatment options, cardiovascular risk estimation is belived to play an even larger role in the future.
Beyond lipids and inflammatory markers, a new type of blood test for cardiovascular risk estimation has emerged in recent years, namely the measurement of extracellular matrix proteins. In our research, we quantify these blood borne proteins amongst other circulating biomarkers and explore how the levels are associated with coronary artery disease and ascending aortic dilatation. The goal is to increase the understanding of these proteins in relation to cardiovascular risk and we hope that this could facilitate clinical use in the future. The research is performed within general population-based cohorts based in Sweden such as the LSH and SCAPIS cohort.
Beyond lipids and inflammatory markers, a new type of blood test for cardiovascular risk estimation has emerged in recent years, namely the measurement of extracellular matrix proteins. In our research, we quantify these blood borne proteins amongst other circulating biomarkers and explore how the levels are associated with coronary artery disease and ascending aortic dilatation. The goal is to increase the understanding of these proteins in relation to cardiovascular risk and we hope that this could facilitate clinical use in the future. The research is performed within general population-based cohorts based in Sweden such as the LSH and SCAPIS cohort.
